555 related articles for article (PubMed ID: 28499411)
1. Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade.
Gambichler T; Strutzmann S; Tannapfel A; Susok L
BMC Cancer; 2017 May; 17(1):327. PubMed ID: 28499411
[TBL] [Abstract][Full Text] [Related]
2. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
3. Clinical Case of the Month: A 57-Year-Old Man with an Axillary Mass.
Desai P; Myers A; Boulmay B; Lopez FA
J La State Med Soc; 2017; 169(3):78-82. PubMed ID: 28644156
[TBL] [Abstract][Full Text] [Related]
4. Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
McDonald MA; Sanghvi P; Bykowski J; Daniels GA
BMC Cancer; 2018 May; 18(1):549. PubMed ID: 29743050
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
[TBL] [Abstract][Full Text] [Related]
7. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report.
Shibata C; Kato J; Toda N; Imai M; Fukumura Y; Arai J; Kurokawa K; Kondo M; Takagi K; Kojima K; Ohki T; Seki M; Yoshida M; Suzuki A; Tagawa K
J Med Case Rep; 2019 Jun; 13(1):168. PubMed ID: 31153385
[TBL] [Abstract][Full Text] [Related]
8. A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity.
Chan PY; Hall P; Hay G; Cohen VML; Szlosarek PW
Pigment Cell Melanoma Res; 2017 Jan; 30(6):558-562. PubMed ID: 28640512
[TBL] [Abstract][Full Text] [Related]
9. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
[TBL] [Abstract][Full Text] [Related]
10. Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy.
Gambichler T; Stockfleth E; Susok L
J Immunother Cancer; 2018 Oct; 6(1):113. PubMed ID: 30376886
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous long-lasting regression of multiple nevi and melanoma metastases after ipilimumab therapy.
Plaquevent M; Greliak A; Pinard C; Duval-Modeste AB; Joly P
Melanoma Res; 2019 Jun; 29(3):311-312. PubMed ID: 31026247
[TBL] [Abstract][Full Text] [Related]
12. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
[TBL] [Abstract][Full Text] [Related]
13. Acral vascular necrosis associated with immune-check point inhibitors: case report with literature review.
Khaddour K; Singh V; Shayuk M
BMC Cancer; 2019 May; 19(1):449. PubMed ID: 31088420
[TBL] [Abstract][Full Text] [Related]
14. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma: A case report.
Yano M; Asami Y; Nishikawa T; Yoshida S; Kamada K; Katoh T; Teramoto Y; Nakamura Y; Yasuda M
Medicine (Baltimore); 2018 Oct; 97(43):e12937. PubMed ID: 30412106
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
[TBL] [Abstract][Full Text] [Related]
17. [Digital ischaemia with fingertip ulcers during ipilimumab therapy].
Zenati N; Charles J; Templier I; Blaise S
Ann Dermatol Venereol; 2020 Mar; 147(3):212-216. PubMed ID: 31864764
[TBL] [Abstract][Full Text] [Related]
18. Paraneoplastic acral vascular syndrome: case presentation and literature review.
AlRasbi S; Al-Badi AH; Al Alawi AM
BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33452070
[TBL] [Abstract][Full Text] [Related]
19. Widespread vitiligo and poliosis following ipilimumab-nivolumab combination therapy.
Nemovi K; Jamali A; Matinpour K; Dasanu CA
J Oncol Pharm Pract; 2023 Jul; 29(5):1278-1282. PubMed ID: 36785936
[TBL] [Abstract][Full Text] [Related]
20. Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports.
Schliep S; Agaimy A; Cavallaro A; Kiesewetter F; Schuler G; Heinzerling L
J Immunother Cancer; 2018 Jan; 6(1):2. PubMed ID: 29332608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
